The psychopharmacology of 5-HT3 receptors

https://doi.org/10.1016/0163-7258(90)90086-HGet rights and content

Abstract

The review presents evidence that 5-HT3 receptors within the brain may contribute to the control of behavior. 5-HT3 receptor antagonists GR38032F, zacopride, ICS205-930 and other agents are very potent in reducing mesolimbic dopamine hyperactivity caused by the injection of amphetamine or infusion of dopamine into the rat nucleus accumbens and amygdala, and the ventral striatum of the marmoset. Such actions are distinguished from those of neuroleptic agents by a failure to reduce normal levels of activity or to induce a rebound hyperactivity after discontinuation of treatment. Indeed, the 5-HT3 receptor antagonists can prevent the neuroleptic-induced rebound hyperactivity. Further evidence that 5-HT3 receptors moderate limbic dopamine function is shown by their ability to reduce both the behavioral hyperactivity and changes in limbicdopamine metabolism caused by DiMe-C7 injection into the ventral tegmental area. The 5-HT3 receptor antagonists also have an anxiolytic profile in the social interaction test in the rat, the light/dark exploration test in the mouse, the marmoset human threat test and behavioral observations in the cynomolgus monkey. They differ from the benzodiazepines by an absence of effect in the rat water lick conflict test and a withdrawal syndrome. Importantly, the 5-HT3 receptor antagonists are highly effective to prevent the behavioral syndrome following withdrawal from treatment with diazepam, nicotine, cocaine and alcohol. Intracerebral injection techniques in the mouse indicate that the dorsal raphe nucleus and amygdala may be important sites of 5-HT3 receptor antagonist action to inhibit aversive behavior. Studies with GR38032F indicate an additional effect in reducing alcohol consumption in the marmoset. The identification and distribution of 5-HT3 receptors in the brain using a number of 5-HT3 receptor ligands. [3H]65630, [3H]zacopride and [3H]ICS205-930 correlates between studies, and the 5-HT3 recognition sites in cortical, limbic and other areas meet the criteria for 5-HT3 receptors to mediate the above behavioral effects. Thus the use of 5-HT3 receptor antagonists reveals an important role for 5-hydroxytryptamine in the control of disturbed behavior in the absence of effect on normal behavior. The profile of action of the 5-HT3 receptor antagonists has generated a major clinical interest in their potential use for schizophrenia, anxiety and in the control of drug abuse.

References (97)

  • B. Costall et al.

    The actions of nicotine and cocaine in a mouse model of anxiety

    Pharmac. Biochem. Behav.

    (1989)
  • J.N. Crawley et al.

    Preliminary report of a simple animal behaviour model for the anxiolytic effects of benzodiazepines

    Pharmac. Biochem. Behav.

    (1980)
  • S.E. File

    The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs

    J. Neurosci. Meth.

    (1980)
  • S.E. File et al.

    Anxiogenic effects in benzodiazepine withdrawal are linked to the development of tolerance

    Brain Res. Bull.

    (1987)
  • R.E. Fitzgerald et al.

    Reduction of nicotine-induced hyperactivity of pCPA

    Pharmac. Biochem. Behav.

    (1985)
  • C.R. Gardner

    Recent developments in 5-HT-related pharmacology of animal models of anxiety

    Pharmac. Biochem. Behav.

    (1986)
  • I. Geller et al.

    The effects of 5-HT on parachlorophenylalanine (pCPA) attenuation of ‘conflict’ behaviour

    Eur. J. Pharmac.

    (1970)
  • S.R. Glaum et al.

    Identification of 5-HT3 binding sites in rat spinal cord synaptosomal membranes

    Eur. J. Pharmac.

    (1988)
  • L.A. Grupp et al.

    Attenuation of alcohol intake by a serotonin uptake inhibitor: evidence for mediation through the reninangiotensin system

    Pharmac. Biochem. Behav.

    (1988)
  • R.M. Hagan et al.

    Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain

    Eur. J. Pharmac.

    (1987)
  • D. Hoyer et al.

    Identification of serotonin 5-HT3 recognition sites by radioligand binding in NG108-15 neuroblastoma-glioma cells

    Eur. J. Pharmac.

    (1987)
  • D.L. Jones et al.

    Injections of dopaminergic, cholinergic, soretonergic and GABA-ergic drugs into the nucleus accumbens: effects on locomotor activity in the rat

    Neuropharmacology

    (1981)
  • G.J. Kilpatrick et al.

    Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species

    Eur. J. Pharmac.

    (1989)
  • J.M. Lakoski et al.

    Cocaine interaction with central monoaminergic systems: electro-physiological approaches

    Trends Pharmac. Sci.

    (1988)
  • W.H. Lyness et al.

    Destruction of 5-hydroxytryptamine neurons and the dynamics of dopamine in nucleus accumbens septi and other forebrain regions in the rat

    Neuropharmacology

    (1981)
  • J.M. Murphy et al.

    Monoamine uptake inhibitors attenuate ethanol intake in alcohol-preferring (P) rats

    Alcohol

    (1985)
  • S.J. Peroutka et al.

    [3H]quipazine labels 5-HT3 recognition sites in rat cortical membranes

    Eur. J. Pharmac.

    (1988)
  • B.P. Richardson et al.

    The pharmacology and function of 5-HT3 receptors

    Trends Neurosci.

    (1986)
  • R.C. Robichaud et al.

    The effects of π-chlorophenylalanine on experimentally induced conflict in the rat

    Life Sci.

    (1969)
  • N.M.J. Rupniak et al.

    The effect of chronic neuroleptic administration on cerebral dopamine receptor function

    Life. Sci.

    (1983)
  • G.J. Sanger et al.

    Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL43694 (granisetron)

    Eur. J. Pharmac.

    (1989)
  • K. Shibata et al.

    Localisation of the site of the anti-conflict action of benzodiazepines in the amygdaloid nucleus of rats

    Brain Res.

    (1982)
  • M.-H. Thiebot et al.

    Attenuation of induced anxiety in rats by chlordiazepoxide: role of raphe dorsalis benzodiazepine binding sites and serotonergic neurons

    Neuroscience

    (1982)
  • J. Traber et al.

    5-HT1A receptor-related anxiolytics

    Trends Pharmac. Sci.

    (1987)
  • C. Waeber et al.

    Localisation by autoradiography of neuronal 5-HT3 receptors in the mouse CNS

    Eur. J. Pharmac.

    (1988)
  • K.J. Watling et al.

    [3H]quaternised ICS205-930 labels 5-HT3 receptor binding sites in rat brain

    Eur. J. Pharmac.

    (1988)
  • D.J.K. Balfour et al.

    Studies on the possible role of brain 5-HT systems and adrenocortical activity in behavioural responses to nicotine and diazepam in an elevatex X-maze

    Psychopharmacology

    (1986)
  • N.M. Barnes et al.

    Identification of 5-HT3 recognition sites in human brain using 3H·zacopride

    J. Pharm. Pharmac.

    (1988)
  • N.M. Barnes et al.

    3H-zacopride identifies 5-HT3 binding sites in rat entorhinal cortex

    Br. J. Pharmac.

    (1988)
  • N.M. Barnes et al.

    3H-zacopride: a ligand for the identification of 5-HT3 recognition sites

    J. Pharm. Pharmac.

    (1988)
  • N.M. Barnes et al.

    Identification of 5-HT3 recognition sites in the ferret area postrema

    J. Pharm. Pharmac.

    (1988)
  • J.M. Barnes et al.

    Identification and characterisation of 5-HT3 recognition sites in human brain tissue

    J. Neurochem.

    (1989)
  • P.B. Bradley

    5-HT3 receptors in the brain

    Nature

    (1987)
  • A. Butler et al.

    Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors

    Br. J. Pharmac.

    (1988)
  • C.J. Carter et al.

    The effects of 5,7-dihydroxytryptamine lesions of extrapyramidal and mesolimbic sites on spontaneous motor behaviour and amphetamine induced stereotypy

    Naunyn-Schmiedebergs Arch. Pharmac.

    (1979)
  • F.C. Colpaert et al.

    Behavioural and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rats

    Psychopharmacology, Berl.

    (1985)
  • R.L. Commissaris et al.

    Interactions of metergoline with diazepam, quipazine and hallucinogen drugs on a conflict behaviour in the rat

    Psychopharmacology, Berl.

    (1982)
  • B. Costall et al.

    Serotonergic modulation of the dopamine response from the nucleus accumbens

    J. Pharm. Pharmac.

    (1976)
  • Cited by (230)

    • Γ-Aminobutyric acid in adult brain: an update

      2019, Behavioural Brain Research
      Citation Excerpt :

      Interestingly, the dendritic tree of CCK + basket cells has an average length of 6300 μ and penetrates all layers [306]. CCK + INs received of serotonergic [307] cholinergic [308] subcortical projection neurons and additionally GABAergic projection from local CalR + INs [308]. CCK + , like PV + INs, make synapses on pyramidal neurons and act on CCKBRs to increase extracellular levels of GABA, which then acts on GABABRs to decrease IPSC amplitude [309].

    • Serotonin receptors in depression and anxiety: Insights from animal studies

      2018, Life Sciences
      Citation Excerpt :

      Many preclinical data indicated the 5-HT3 receptor as a potential target in the treatment of anxiety (Table 6, reviewed in [174]). Behavioral studies demonstrated that 5-HT3 receptor antagonists were effective in rodent anxiety models, e.g., social interaction test in rats or light/dark exploration test in mice, secondary to the limbic hyperactivity response blockade (reviewed in [175]). The atypical 5-HT3 receptor antagonist, VA21B7, showed anxiolytic-like activity in the elevated plus maze and punished-drinking in rats [176].

    • Tropisetron upregulates cannabinoid CB <inf>1</inf> receptors in cerebellar granule cells: Possible involvement of calcineurin

      2011, Brain Research
      Citation Excerpt :

      They also indicated that classical calcineurin inhibitors such as cyclosporine or tacrolimus (FK506) upregulate CB1 receptor expression (Kramer et al., 2003). Regarding the fact that tropisetron and CB1 receptor agonists share various pharmacological effects including anti-emetic (Scuderi, 2001) analgesic (Riering et al., 2004), anxiolytic (Costall et al., 1990; Lecrubier et al., 1993) anti-inflammatory (Schneider et al., 2004; Seidel et al., 2004) properties and taking into account the ability of calcineurin to control CB1 expression (Kramer et al., 2003), we aimed to investigate possible effects of tropisetron on calcineurin activity and CB1 receptor expression as well as its secondary messenger, cAMP, content in primary cerebral granule neuron cultures. Their high content of calcineurin (Klee et al., 1998) makes cerebellar granule cells ideal for investigating effects of tropisetron on calcineurin activity.

    View all citing articles on Scopus
    View full text